DDInter1747 DDInter1351
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zileuton
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Osilodrostat may lead to a major life threatening interaction when taken with Tizanidine
Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib